<p>The clearance of erythromycin in healthy subjects was 0.53 ± 0.13 l/h/kg after a 125mg intravenous dose.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Sun H, Frassetto LA, Huang Y, Benet LZ: Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease. Clin Pharmacol Ther. 2010 Apr;87(4):465-72. doi: 10.1038/clpt.2009.247. Epub 2010 Jan 20. (PubMed ID 20090676)" href="#reference-A174457">11</a></sup> In a clinical study of healthy patients and patients with liver cirrhosis, clearance of erythromycin was significantly reduced in those with severe liver cirrhosis.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Barre J, Mallat A, Rosenbaum J, Deforges L, Houin G, Dhumeaux D, Tillement JP: Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity. Br J Clin Pharmacol. 1987 Jun;23(6):753-7. doi: 10.1111/j.1365-2125.1987.tb03111.x. (PubMed ID 3606934)" href="#reference-A180604">17</a></sup> The clearance in cirrhotic patients was 42.2 ± 10.1 l h–1 versus 113.2 ± 44.2 l h-1 in healthy patients.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Barre J, Mallat A, Rosenbaum J, Deforges L, Houin G, Dhumeaux D, Tillement JP: Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity. Br J Clin Pharmacol. 1987 Jun;23(6):753-7. doi: 10.1111/j.1365-2125.1987.tb03111.x. (PubMed ID 3606934)" href="#reference-A180604">17</a></sup></p>